Aprameya Enginee (APRAMEYA)

Score breakdown: P/E: 2/3 · ROCE: 2/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

At first glance, Aprameya Enginee looks like the kind of compounder I would circle: a small medical-equipment firm compounding rapidly while still trading at a reasonable price. The market cap is ₹376 Cr, yet latest quarter net profit is ₹7 Cr and sales ₹42 Cr. The trailing P/E of 15.30 is not demanding for a business with such momentum. Sales growth of 354.58% and profit growth of 490.75% are extraordinary, but Graham taught me to treat a single year’s rocket numbers with suspicion. One year can be a low base, a government order, or a temporary tailwind. The 52-week range of ₹135 to ₹249 shows the market has already re-rated this stock significantly. ROCE of 31.12% is genuinely impressive; it suggests the company is earning good returns on capital employed. A Piotroski F-Score of 7/9 also hints at improving financials. Promoter holding of 74.05% is another positive—owners have skin in the game. That said, the absence of book value, ROE, and debt/equity data is a yellow flag. I cannot compute the true margin of safety or know whether this growth is built on leverage. Dividend yield is zero, so the only return is future price appreciation and reinvested growth—fine if growth persists, dangerous if it stalls. The PEG of 0.04 is mathematically seductive but built on a 490% profit growth number that I refuse to extrapolate. In the spirit of Graham: buy a business not a spreadsheet. I would wait for more audited history, check whether the latest quarter is repeatable, and monitor the balance-sheet disclosures before assigning a full intrinsic value.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer